Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis

Nanomedicine

Volumn 5, Issue 7, 2010, Pages 1065-1074

  Zhou, Hui Fang ^a   Hu, Grace ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a   Pham, Christine Tn ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiangiogenics; combination therapy; K BxN arthritis model; nanotherapeutics; rheumatoid arthritis

Indexed keywords

ALKALINE PHOSPHATASE; CYTOKINE; FUMAGILLIN; HEMOGLOBIN; METHOTREXATE; NANOPARTICLE; PROTEOGLYCAN; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE EROSION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE DRUG DOSE; SYNOVITIS; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTHRITIS, EXPERIMENTAL; MALE; METHOTREXATE; MICE; MICE, INBRED C57BL; NANOMEDICINE;

EID: 77957562101     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.78     Document Type: Article

References (21)

1. Sizova L: Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br. J. Clin. Pharmacol. 66(2), 173-178 (2008).
2. Van Der Bijl AE, Goekoop-Ruiterman Y P, De Vries-Bouwstra JK et al.: Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 56(7), 2129-2134 (2007).
3. 3-targeted nanotherapy suppresses inflammatory arthritis in mice. Faseb J. 23(9), 2978-2985 (2009). □□ First study to show that avβ3-targeted nanoparticles conjugated to fumagillin accumulate specifically in inflamed joints and suppress the progression of experimental arthritis.
4. Duda DG, Jain RK, Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25(26), 4033-4042 (2007). □□ Presents the rationale and current understanding of antiangiogenics and their therapeutic potential in combination with chemoradiotherapy.
5. Culy C: Bevacizumab: antiangiogenic cancer therapy. Drugs Today (Barc) 41(1), 23-36 (2005).
6. Fukumura D, Jain RK: Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc. Res. 74(2-3), 72-84 (2007).
7. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM: Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JAAC Cardiovasc. Imaging 1(5), 624-634 (2008). □□ Shows that integrin-targeted fumagillin nanoparticles can induce sustained antiangiogenic response in a model of atherosclerosis when combined with a statin.
8. Adkison AM, Raptis SZ, Kelley DG, Pham CT: Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J. Clin. Invest. 109(3), 363-371 (2002).
9. Schnell MA, Hardy C, Hawley M, Propert KJ, Wilson JM: Effect of blood collection technique in mice on clinical pathology parameters. Human Gene Ther. 13(1), 155-161 (2002).
10. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J. Clin. Invest. 103(1), 47-54 (1999).
11. Bulte JWM, Lanza GM, Fuhrhop RW et al.: Gd-DTPA perfuorocarbon emulsions as a novel paramagnetic particulate contrast medium: T1 and T2 relaxometry. Presented at: Proceedings of International Society for Magnetic Resonance in Medicine 6th Annual Meeting. Sydney, Australia, 18-24 April (1998) (Abstract 209).
12. Lena N, Imbert AM, Brunet P, Cano JP, Carcassonne Y: Kinetics of methotrexate and its metabolites in red blood cells. Cancer Drug Deliv. 4(2), 119-127 (1987).
13. Chan ES, Cronstein BN: Methotrexate - how does it really work? Nat. Rev. Rheumatol. 6(3), 175-178 (2010). □ □ Details the complex and multifaceted mechanisms that make methotrexate efficacious in the treatment of inflammatory disorders.
14. 3: angiogenesis and apoptosis. Cell Adhes. Commun. 3(4), 367-374 (1995).
15. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J: Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99(13), 1726-1732 (1999).
16. Brdlik CM, Crews CM: A single amino acid residue defines the difference in ovalicin sensitivity between type I and II methionine aminopeptidases. J. Biol. Chem. 279(10), 9475-9480 (2004).
17. De Bandt M, Grossin M, Weber AJ et al.: Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum. 43(9), 2056-2063 (2000). □ Early report showing that TNP-470, a soluble form of fumagillin, can prevent the development of experimental arthritis.
18. Herbst RS, Madden TL, Tran HT et al.: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J. Clin. Oncol. 20(22), 4440-4447 (2002).
19. Neurath MF, Hildner K, Becker C et al.: Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): A mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol. 115(1), 42-55 (1999).
20. Szekanecz Z, Besenyei T, Paragh G, Koch AE: New insights in synovial angiogenesis. Joint Bone Spine 77(1), 13-19 (2009).
21. Szekanecz Z, Besenyei T, Szentpetery A, Koch AE: Angiogenesis and vasculogenesis in rheumatoid arthritis. Curr. Opin. Rheum. 22(3), 299-306 (2010). □ Provides a current understanding of the role of angiogenesis in rheumatoid arthritis, and summarizes the possibilities of therapeutic intervention.